

Table S4. Rs4646 genotypes distribution according to patients' baseline characteristics

	rs4646				
	GG N=451	GT N=373	TT N=62	χ^2 p value	Kruskal-Wallis p value
BMI, N (%)					
<24	156 (34.6)	253 (67.8)	19 (30.6)	0.366	
≥24	285 (63.2)	112 (30.0)	40 (64.5)		
Missing	10 (2.2)	8 (2.1)	3 (4.8)		
Tumor size, N (%)					
pT1	282 (62.5)	229 (61.4)	43 (69.4)	0.07	
pT2	135 (29.9)	119 (31.9)	9 (14.5)		
pT3-4	27 (6.0)	17 (4.6)	6 (9.7)		
Missing	7 (1.6)	8 (2.1)	4 (6.5)		
Nodal Status, N (%)					
pN0	216 (48.0)	183 (49.1)	36 (58.1)	0.373	
pN1-3	219 (51.0)	185 (49.6)	26 (41.9)		
Missing	6 (1.0)	5 (1.3)	0 (0.0)		
Grade, N (%)					
G1	72 (16.0)	67 (18.0)	11 (17.7)	0.716	
G2	249 (55.2)	186 (49.9)	31 (50.0)		
G3	103 (22.8)	93 (24.9)	13 (21.0)		
Missing	27 (6.0)	27 (7.2)	7 (11.3)		
Tamoxifen, years (median, IQR)	2.1 (1.9-2.5)	2.1 (1.9-2.5)	2.1 (1.6-2.8)		0.474
Letrozole, years (median, IQR)	3.2 (2.8-5.0)	3.1 (2.4-5.0)	3.0 (2.6-5.0)		0.431